Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.

You may also be interested in...



Pfizer On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 2 of 2)

On the way back to his old job in the U.S., after a stint in Shanghai as head of research in Asia, VP Richard Connell, head of Preclinical Outsourcing says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)

On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships

On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

Related Content

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel